Researchers from the University of North Carolina Lineberger Comprehensive Cancer Center estimate that screening for and treating prostate cancer in men ages 70 years or older, which is not recommended by national guidelines, cost Medicare more than $1.2 billion over a three year period for each group of men diagnosed in the United States each year.
Published September 13 in the journal JAMA Oncology, the study examined the costs associated with screening for prostate cancer, including treatment, for three years after diagnosis. They estimated that for men diagnosed in each of the years 2004, 2005, 2006 and 2007, the total cost for treating and screening for each group would be $1.2 billion for three years after diagnosis.
The study also showed that of the total, $451 million was spent on men who were diagnosed with prostate cancer that is graded with a Gleason score of 6, which is considered to be low-grade disease and best managed using active surveillance rather than aggressive treatment.
“The tough discussions that happen in health economics are often cases where care is beneficial, but costly,” said Dr. Justin Trogdon, associate professor of health policy management in the UNC Gillings School of Global Public Health and the study’s first author. “That’s a hard trade-off, but this one is actually a scenario in which care probably is not beneficial and is also costly. Our study puts a dollar figure on just how costly this is.”
The researchers said it is widely recognized that screening for prostate cancer should stop in men at age 70. The U.S. Preventive Services Task Force recommends against prostate cancer screening in men above age 70, citing, among other reasons, that the harms from screening are “at least moderate” or greater for men in that age group because of risk of false-positives, harms from biopsy and harms from treatment, which can include sexual dysfunction and urinary incontinence.
“For patients who are diagnosed with prostate cancer at an older age, because the cancer is often slow-growing, it is unlikely to be the cause of their mortality,” said Dr. Ronald C. Chen, associate professor in the UNC School of Medicine’s Department of Radiation Oncology and the study’s corresponding author. “So, we are not only spending U.S. health care dollars diagnosing an issue that probably isn’t going to be a problem for patients, but when we treat these patients who don’t need treatment, they suffer unnecessary side effects such as urinary incontinence or sexual dysfunction.”
For the retrospective study, researchers used the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Medicare-linked claims database to analyze costs related to diagnosis and work-up, treatment, follow-up and side-effect management for nearly 50,000 men 70 years of age or older who were diagnosed with prostate cancer between 2004 and 2007.
They estimated the cost of diagnosing and treating men for three years after diagnosis, as that is a typical time frame in which patients receive treatment.
The researchers found that for men diagnosed in each year, the total three-year cost was $1.2 billion. For men diagnosed in 2004, for example, the estimated cost to Medicare was $1.2 billion across three years. The median per-patient cost within three years after prostate cancer diagnosis was $14,453, with treatment costs accounting for 73 percent of that total. The researchers estimated a cost savings of $320 million per year for Medicare if patients who have a Gleason score of 6 were to choose active surveillance.
“Studies indicate that we are testing for prostate cancer in people for whom the potential harms outweigh the potential benefits, and then we are treating — actually overtreating — people for a cancer that may have little to no impact on their life expectancy,” Dr. Chen said. “Not following guidelines could be putting people’s health at risk, and it is costing the U.S. health care system a lot of money. It would make more sense to put these resources into other areas that could do more good for patients.”
The researchers report that foregoing aggressive treatment of low-risk prostate cancer in older patients, especially those with other health issues, could prevent harm due to treatment-related side effects, while also providing a savings to Medicare. They suggest that screening men with at least a 10-year life expectancy, and selectively treating those with more aggressive cancer, may be one approach to eliminating unnecessary spending while maximizing patient outcomes.